阿达木单抗对非感染性中间型、后型和全葡萄膜炎患者视觉功能的影响:VISUAL-1和VISUAL-2试验
该事后分析基于VISUAL-1(活动性,217例)和VISUAL-2(非活动性,226例)两项临床试验,评估阿达木单抗对糖皮质激素依赖性非感染性中间型、后型和全葡萄膜炎患者视觉功能与生活质量的影响。VISUAL-1中,阿达木单抗组NEI VFQ-25变化与安慰剂组差异为4.20(95%CI 1.04~7.36;P=0.01);VISUAL-2中差异为2.12(95%CI -0.81~5.04;P=0.16)。纵向模型显示两组试验中阿达木单抗与安慰剂差异均显著。
要点
- VISUAL-1中阿达木单抗组NEI VFQ-25变化与安慰剂组差异为4.20(95%CI 1.04~7.36;P=0.01)。
- VISUAL-2中阿达木单抗组与安慰剂组NEI VFQ-25变化差异为2.12(95%CI -0.81~5.04;P=0.16)。
- 纵向模型显示VISUAL-1和VISUAL-2中阿达木单抗与安慰剂差异分别为3.07(95%CI 2.09~4.06;P<0.001)和4.66(95%CI 0.05~9.26;P=0.048)。
核心结论
- 该事后分析提示,阿达木单抗与非感染性中间型、后型和全葡萄膜炎患者报告视觉功能的统计学显著且临床有意义的改善相关。
研究设计与样本
- 为VISUAL-1和VISUAL-2临床试验的事后分析,纳入成人活动性(VISUAL-1)和非活动性(VISUAL-2)非感染性中间型、后型和全葡萄膜炎患者。
- VISUAL-1共217例(阿达木单抗110例,安慰剂107例),VISUAL-2共226例(阿达木单抗115例,安慰剂111例),采用意向性治疗分析。
- 两项试验于2010年8月10日至2015年5月14日在美国、加拿大、欧洲、以色列、澳大利亚、拉丁美洲和日本开展。
- 患者随机接受阿达木单抗80 mg皮下负荷剂量后每2周40 mg或安慰剂治疗80周,所有患者均进行泼尼松减量,VISUAL-1患者接受初始泼尼松冲击。
主要发现
- VISUAL-1中,NEI VFQ-25从最终评分至最佳评分的变化:阿达木单抗组-1.30 vs 安慰剂组-5.50,差异4.20(95%CI 1.04~7.36;P=0.01)。
- VISUAL-2中,NEI VFQ-25自基线的变化:阿达木单抗组3.36 vs 安慰剂组1.24,差异2.12(95%CI -0.81~5.04;P=0.16)。
- 纵向模型显示,VISUAL-1中阿达木单抗与安慰剂NEI VFQ-25差异为3.07(95%CI 2.09~4.06;P<0.001),VISUAL-2中差异为4.66(95%CI 0.05~9.26;P=0.048)。
- VISUAL-1中阿达木单抗组NEI VFQ-25为74.15 vs 安慰剂组71.08;VISUAL-2中阿达木单抗组82.39 vs 安慰剂组77.73。
关键数值与推荐
- NEI VFQ-25复合评分问卷评分范围0至100分,评分越高表示视觉相关生活质量越好。
- VISUAL-1中NEI VFQ-25变化自第6周前达到的最佳状态至最终或提前终止访视;VISUAL-2中自基线状态至最终或提前终止访视。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Adalimumab was recently approved for the treatment of noninfectious intermediate uveitis, posterior uveitis, and panuveitis. OBJECTIVE: To assess the effect of adalimumab on the visual functioning and quality of life in patients with corticosteroid-dependent noninfectious intermediate uveitis, posterior uveitis, and panuveitis. DESIGN: A post hoc analysis of clinical trials of adults with active (VISUAL-1) and inactive (VISUAL-2) noninfectious intermediate uveitis, posterior uveitis, and panuveitis was conducted in the United States, Canada, Europe, Israel, Australia, Latin America, and Japan. A total of 217 patients (110 adalimumab, 107 placebo) in VISUAL-1 and 226 patients (115 adalimumab, 111 placebo) in VISUAL-2 were studied using intent-to-treat analyses. The clinical trials were conducted between August 10, 2010, and May 14, 2015. INTERVENTIONS: In VISUAL-1 and VISUAL-2, patients were randomized to receive adalimumab, 80-mg, subcutaneous loading dose followed by 40 mg every other week or placebo for 80 weeks. All patients underwent prednisone tapering, with patients in VISUAL-1 receiving an initial prednisone burst. MAIN OUTCOMES AND MEASURES: The 25-item National Eye Institute Vision Function Questionnaire (NEI VFQ-25) composite score questionnaire assessed the impact of visual impairment from the patient's perspective; scores on the questionnaire range from 0 to 100, with higher scores indicating better vision-related quality of life. The change in NEI VFQ-25 from best state achieved prior to week 6 (VISUAL-1) and from baseline state (VISUAL-2) to the final or early termination visit was determined in each group and statistically compared using analysis of variance. The temporal effects of adalimumab and placebo on NEI VFQ-25 were investigated using a longitudinal model. RESULTS: Of the 217 patients in VISUAL-1, 124 (57.1%) were women; the mean (SD) age was 42.7 (14.9) years. Of the 226 patients in VISUAL-2, 138 (61.1%) were women; the mean (SD) age was 42.5 (13.4). In VISUAL-1, the change from final score to best score in NEI VFQ-25 was -1.30 for adalimumab and -5.50 for placebo-a difference of 4.20 (95% CI, 1.04 to 7.36; P = .01) associated with adalimumab compared with placebo. In VISUAL-2, the change from baseline NEI VFQ-25 was 3.36 for adalimumab and 1.24 for placebo-a difference of 2.12 (95% CI, -0.81 to 5.04; P = .16). In both trials, the longitudinal models showed a significant difference in NEI VFQ-25 between adalimumab and placebo of 3.07 (95% CI, 2.09 to 4.06; P < .001) and 4.66 (95% CI, 0.05 to 9.26; P = .048) in the VISUAL-1 (74.15 vs 71.08) and VISUAL-2 (82.39 vs 77.73) trials, respectively. CONCLUSIONS AND RELEVANCE: This post hoc analysis suggests that adalimumab is associated with statistically significant and clinically meaningful improvements in patient-reported visual functioning for patients with noninfectious intermediate uveitis, posterior uveitis, and panuveitis. TRIAL REGISTRATION: clinicaltrials.gov Identifiers: NCT01138657 (VISUAL-1) and NCT01124838 (VISUAL-2).
引用
- Sheppard J, Joshi A, Betts KA, et al. Effect of Adalimumab on Visual Functioning in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials. JAMA Ophthalmol. 2017. PMID: 28426849. doi:10.1001/jamaophthalmol.2017.0603
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。